Literature DB >> 8400625

Assessment of the effectiveness of animal developmental toxicity testing for human safety.

L M Newman1, E M Johnson, R E Staples.   

Abstract

Evaluations of studies for four well-known human developmental toxicants clearly suggest that a margin of exposure of 1/100th the NOAEL for the most sensitive animal species tested provides adequate safety for the human conceptus. The lowest reported human teratogenic exposures occurred at doses at least one log above the estimated "safe" or acceptable daily exposure based on the most sensitive animal species, that is, 1/100th animal NOAEL. (The MOE ranged from < 1 to 10.). The data and analyses are consistent with the conclusion that, regardless of the type of in utero effect produced in animals, the margin of safety of 100 is likely to protect the human conceptus in utero from developmental perturbation, and it is a scientifically reasonable and conservative default number.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400625     DOI: 10.1016/0890-6238(93)90025-3

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  8 in total

Review 1.  Properties of thalidomide and its analogues: implications for anticancer therapy.

Authors:  Steven K Teo
Journal:  AAPS J       Date:  2005-03-22       Impact factor: 4.009

Review 2.  Bridging epidemiology and model organisms to increase understanding of endocrine disrupting chemicals and human health effects.

Authors:  Tracey J Woodruff
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-26       Impact factor: 4.292

Review 3.  Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Authors:  Sarah A Holstein; Philip L McCarthy
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 4.  Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.

Authors:  J Kay Noel; Sheila Crean; Janet E Claflin; Gayatri Ranganathan; Heather Linz; Michael Lahn
Journal:  Med Oncol       Date:  2008-01-19       Impact factor: 3.064

5.  Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death.

Authors:  Jürgen Knobloch; Ingo Schmitz; Katrin Götz; Klaus Schulze-Osthoff; Ulrich Rüther
Journal:  Mol Cell Biol       Date:  2008-01       Impact factor: 4.272

6.  Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Authors:  Philip P Chamberlain; Antonia Lopez-Girona; Karen Miller; Gilles Carmel; Barbra Pagarigan; Barbara Chie-Leon; Emily Rychak; Laura G Corral; Yan J Ren; Maria Wang; Mariko Riley; Silvia L Delker; Takumi Ito; Hideki Ando; Tomoyuki Mori; Yoshinori Hirano; Hiroshi Handa; Toshio Hakoshima; Thomas O Daniel; Brian E Cathers
Journal:  Nat Struct Mol Biol       Date:  2014-08-10       Impact factor: 15.369

7.  Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells.

Authors:  Yoav Mayshar; Ofra Yanuka; Nissim Benvenisty
Journal:  J Cell Mol Med       Date:  2010-06-17       Impact factor: 5.310

Review 8.  Hazard identification and predictability of children's health risk from animal data.

Authors:  LaRonda L Morford; Judith W Henck; William J Breslin; John M DeSesso
Journal:  Environ Health Perspect       Date:  2004-02       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.